Related Experiment Video
Updated: Aug 7, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Targeting interleukin-2 as a treatment for psoriasis
1Department of Dermatology, North Staffordshire Hospital, Stoke-on Trent, UK. salim@doctors.org.uk
Interleukin (IL)-2 is known to play a key role in the pathophysiology of psoriasis by activating T-cells. In recent years, therapies have been developed to specifically prevent T-cell activation by blocking the production of IL-2 or by inhibiting its action. These new therapies are discussed.
Interleukin (IL)-2 is known to play a key role in the pathophysiology of psoriasis by activating T-cells. In recent years, therapies have been developed to specifically prevent T-cell activation by blocking the production of IL-2 or by inhibiting its action. These new therapies are discussed.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
iPS Cell Differentiation
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Tumor Immunotherapy
Inhibitors of Viral Protein Synthesis

